Skip to main content

Table 2 Lead time between first ctDNA detection and clinical disease recurrence

From: Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis

Study

Median lead time (months)

Lead time range (months)

ctDNA testing time

Molinero 2022 [28]

6.1

0-30.5

After adjuvant

Gupta 2023 [25]

3.85

0.6–11

After adjuvant

Stecklein 2023 [35]

4.7

Not reported

After all treatment

Turner 2023 [36] (observation arm)*

4.1

Not reported

After all treatment*

Turner 2023 [36)] (intervention arm)*

1.6

Not reported

After all treatment*

Shaw 2024 [34]

8

0–19

After all treatment

Chen 2017 [23]

4.2

0.07–8.87

During adjuvant

Chen 2020 [24]

Not reported

0.07–20.93

First day of adjuvant

  1. * Prospective study where patients where ctDNA positive patients were allocated to an intervention arm (pembrolizumab) or observation arm. Initially ctDNA testing started after all treatment. After August 6 2019 amendment (154/208 patients were already enrolled), ctDNA testing started before or during radiotherapy